Skip to main content

Peer Review reports

From: A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy

Original Submission
20 Oct 2023 Submitted Original manuscript
7 Nov 2023 Reviewed Reviewer Report
4 Jan 2024 Reviewed Reviewer Report
28 Mar 2024 Author responded Author comments - Sharon Wolters
25 Apr 2024 Reviewed Reviewer Report
26 Apr 2024 Reviewed Reviewer Report
23 May 2024 Author responded Author comments - Sharon Wolters
Resubmission - Version 2
28 Mar 2024 Submitted Manuscript version 2
Publishing
29 May 2024 Editorially accepted
24 Jun 2024 Article published 10.1186/s12883-024-03697-x

You can find further information about peer review here.

Back to article page